Intravesical BCG Administration to Patients With Invasive Bladder Cancer
NCT ID: NCT02365207
Last Updated: 2019-11-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
6 participants
INTERVENTIONAL
2013-11-30
2019-04-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer
NCT02311101
PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer
NCT02326168
Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)
NCT06350838
Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer
NCT05580354
Analyzing the Urine During BCG Instillation in Bladder Cancer Patients for Disease Followup
NCT06153849
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
After completion of BCG treatments the patient will undergo a cystectomy. A portion of bladder tumor tissue and lymph nodes will be collected for research purposes during the cystectomy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BCG treatment of invasive bladder cancer
Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
BCG strain of Mycobacterium bovis
Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BCG strain of Mycobacterium bovis
Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Be able to give informed consent
3. Be age 18 or older
4. Not be in an immunosuppressed state (e.g. HIV+, use of chronic steroids \>1 month)
Exclusion Criteria
2. Unable to give informed consent
3. \< 18 or older
4. Is in an immunosuppressed state (e.g. HIV+, use of chronic steroids \>1 month)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of Texas Health Science Center at San Antonio
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Svatek, MD
Role: PRINCIPAL_INVESTIGATOR
University of Texas
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MARC - The University of Texas Health Science Center
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.